PT-141 (Bremelanotide) Research Guide: Melanocortin System, Sexual Function Biology, and MC4R Pharmacology

By Justin Cartier

Part of our overview of immune, reproductive and specialty peptides.

PT-141, or bremelanotide, is a peptide studied for sexual desire and arousal. Here’s the twist that makes it unusual: it works in the brain, not the body’s blood vessels. It flips on melanocortin receptors, MC3R and MC4R, that drive desire at its source.^[1] This guide covers what it does, how it works, what the studies show, how it stacks up against Viagra and Cialis, the side effects, and what to check when sourcing it.

It crossed the FDA finish line in 2019 as Vyleesi, the first non-hormonal, brain-acting treatment for low sexual desire in premenopausal women. That’s a real departure from what came before. Sildenafil (Viagra) and tadalafil (Cialis) act on blood vessels. This synthetic peptide acts on the brain, which is why it can help when the plumbing works fine but the arousal signal never shows up. Its origin story is odd, too. It came out of work on Melanotan II, a tanning compound that startled researchers by causing erections, and that surprise redirected the whole program toward sexual function.

Research-use disclaimer: research-grade PT-141 is sold for laboratory research only and isn’t the same as the approved Vyleesi drug. It isn’t for human use. The notes below describe published lab and human studies, not medical advice.

What does the PT-141 peptide do?

It switches on melanocortin receptors in the brain, mainly MC3R and MC4R, and that’s what drives desire. The PDE5 blood-vessel pathway Viagra leans on? It doesn’t touch it. Palatin Technologies built the molecule out of Melanotan II, reshaping it for cleaner MC4R signaling. Shadiack and colleagues, in Current Topics in Medicinal Chemistry, lay out how a whole set of melanocortin agents, bremelanotide included, share this scaffold and point at the same central pathways.^[1]

Once it’s injected, the peptide slips into the brain and binds MC4R neurons in the hypothalamus and brainstem. Pfaus, reviewing the neurobiology in CNS Spectrums, notes that MC4R clusters mostly in the medial preoptic area, a region tied to desire and motivation for decades.^[2] Light up MC4R there and dopamine rises in the brain’s reward circuit. That dopamine bump is the actual signal behind the libido shift.

Mechanism: MC3R, MC4R, and central arousal

The whole thing happens in the brain, not below the belt. Semple and colleagues, in Endocrinology, used gene-knockout mice to pin MC4R as the controller of sexual function, which rules out a blood-vessel role entirely.^[3] Earlier, Wessells, writing in Peptides, had shown that melanocortin receptors in the brain and spinal cord can produce erections with none of the vessel-widening PDE5 drugs depend on.^[4] That gap, brain versus blood vessel, is the single biggest difference between this peptide and the Viagra class.

And the animal data hold up. Molinoff and colleagues, in the Annals of the New York Academy of Sciences, reported it producing erections in rats and monkeys in a dose-dependent way, by injection and by nasal spray.^[5] The same line of work tracked MC3R and MC4R effects on grooming and sexual-approach behavior in female rodents, so this isn’t a male-only story.

How long does PT-141 take to work?

In published human trials, it gets going 30 to 60 minutes after an injection under the skin. Blood levels peak around 60 to 90 minutes, and the effect peaks soon after. The window runs roughly 8 to 12 hours, longer than the usual Viagra-type stretch. A nasal spray starts faster, in 15 to 30 minutes, but it pays for the speed with lower absorption.

Is PT-141 better than Viagra or Cialis?

“Better” really depends on the cause. PDE5 inhibitors relax blood-vessel muscle in response to arousal that’s already there. This peptide does something earlier in the chain, manufacturing the arousal itself. So if the problem is blood flow and the brain’s signal is intact, the PDE5 drugs are the standard answer. If the brain’s signal is the missing piece, the melanocortin route is the better-matched target. The two classes aren’t rivals. They unblock different bottlenecks.

For premenopausal women with low sexual desire, the clinical term being HSDD, bremelanotide is the FDA-approved choice as Vyleesi. There’s no Viagra-type drug approved for low desire in women, and that’s precisely the gap it fills in sexual health.

Dosage and routes

The approved Vyleesi dose is 1.75 mg under the skin, taken at least 45 minutes before activity, capped at once per 24 hours and eight times a month. Research protocols have run injection, nasal spray, and IV routes across doses from 0.3 mg to 6 mg, depending on the endpoint. Research-grade peptide arrives as a lyophilized powder you reconstitute with bacteriostatic water, while the Vyleesi auto-pen delivers the fixed approved amount.

Side effects and safety

Nausea leads the list, reported by roughly 40 percent of subjects after the first dose and easing off with later ones. Flushing, headache, and a brief rise in blood pressure show up too. There’s also skin darkening, mostly on the face and gums, that can appear with long-term dosing, since the melanocortin system also handles pigment, but the schedules that cause visible darkening sit well above the Vyleesi label. One real caution: it shouldn’t be used with uncontrolled high blood pressure or known heart disease, because of that small, brief pressure bump after each dose.

Rodent safety data turned up no long-term toxicity at standard preclinical doses. What’s still open is the off-target risk of chronically switching on the melanocortin system in people, which the clinical trials haven’t fully answered yet.

Is PT-141 legal?

The finished drug Vyleesi is FDA-approved and prescription-only in the US but has no Health Canada marketing authorization, so research-grade PT-141 sold under research-use-only labels is a separate product from that prescription pen; our guide to buying peptides in Canada explains how the research-chemical rules work.

Can PT-141 be used by both men and women?

In rodent and monkey work, melanocortin activation shifts sexual behavior in both sexes. Human research has tested bremelanotide in men and women alike for arousal endpoints. The FDA approval, though, is narrow: premenopausal women with HSDD. Off-label use in men shows up in the literature, including the original Palatin nasal-spray trials in erectile dysfunction. Anyone studying the peptide in either sex should be working under approved review-board protocols, full stop.

Comparison with other melanocortin agents

It runs with a small crowd of lab-made melanocortin agonists, though the family resemblance only goes so far. Melanotan II is the parent scaffold everything traces back to. Then there’s setmelanotide, sold as Imcivree, a selective MC4R agonist that won approval for certain genetic obesity disorders. Same receptor pharmacology across all three, but the selectivity and the approved uses pull apart fast. Setmelanotide gets dosed daily for body weight, never acutely for desire. Melanotan II is mostly a pigment-and-appetite story. And PT-141 is the lone one with an arousal-disorder approval to its name. So any head-to-head has to keep those selectivity and dosing gaps in view.

Red flags to watch for when sourcing PT-141

A few warning signs separate a clean batch from a bad one. The first is a missing or vague Certificate of Analysis: no batch-specific COA from an independent third-party lab, or one that quotes a purity figure with no batch code, is a reason to walk away. The second is a lone HPLC number like “98 percent” with no chromatogram trace attached, because only the trace shows whether one clean peak or a spread of side-products sits behind that claim. The clearest tell is the mass: bremelanotide has an expected weight near 1,025 Da, so an MS readout that misses that figure means the vial is not what the label says. Add missing endotoxin and sterility data as a deal-breaker for any in-vivo or cell-culture work, and remember that research-only material is never the same product as the FDA-approved Vyleesi pen.

If your study hinges on purity, order peptides in Canada and review the analytical data before ordering.

PT-141 questions

What does the PT-141 peptide do?

It’s a melanocortin receptor agonist that switches on MC3R and MC4R in the brain. The result is more dopamine in reward-related brain regions, which drives sexual desire without working through blood vessels.

How long does it take for PT-141 to work?

It starts 30 to 60 minutes after an injection under the skin; a nasal spray is faster at 15 to 30 minutes. The effect lasts about 8 to 12 hours.

Do I need a prescription for PT-141?

Yes. The finished drug, Vyleesi bremelanotide injection, is prescription-only in the United States. It isn’t approved as a finished drug in Canada. Research-grade material is legal as a research chemical under research-use-only labels.

Is PT-141 better than Viagra or Cialis?

The two classes target different mechanisms. PDE5 inhibitors act on blood-vessel muscle; PT-141 acts in the brain to drive arousal itself. The right tool depends on whether the bottleneck is blood flow or the brain’s signal.

What are the side effects of PT-141?

The most common is nausea, about 40 percent after the first dose and dropping with later ones. Flushing, headache, a brief blood-pressure rise, and skin darkening with long-term high-dose use also show up. It shouldn’t be used with uncontrolled high blood pressure.

Key data point: in knockout-mouse work, MC4R neurons alone were enough to drive sexual function, which nails down the melanocortin pathway as central and brain-based rather than a blood-vessel effect.^[3]

Summary

PT-141, or bremelanotide, is the only FDA-approved peptide for sexual desire problems. It acts in the brain on MC3R and MC4R, lifting dopamine and driving arousal through a mechanism that’s completely unlike Viagra-type drugs. The human and rodent dataset is well developed. The main side effects are brief nausea and a small blood-pressure rise, and the long-term effects of chronic melanocortin activation are still being studied. Researchers using research-grade material should source through validated suppliers and follow approved protocols.

Sources: [1] Melanocortins in male and female sexual dysfunction (bremelanotide class), PubMed. [2] Neurobiology of bremelanotide for HSDD (MC4R, mPOA), PubMed. [3] MC4R neurons sufficient for sexual function in male mice, PubMed. [4] Melanocortinergic control of penile erection, PubMed. [5] PT-141, a melanocortin agonist for sexual dysfunction (animal data), PubMed.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.